WASHINGTON — The Trump administration wants states to experiment with drug prices — but not too much.

In a pair of decisions Wednesday, top health officials offered the first clear signals of just how far they will let state Medicaid agencies go when it comes to negotiating discounts for prescription drugs. The administration declined to approve a bolder proposal from Massachusetts to use a formulary to exclude some drugs from Medicaid coverage, a common negotiating tactic for commercial plans. At the same time, it approved a separate idea from Oklahoma to let the state’s Medicaid program negotiate extra rebates if a given drug isn’t as effective as expected.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy